阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗肝细胞癌术后复发的临床疗效  

Clinical efficacy of first‐line treatment of atelizumab plus bevacizumab for recurrent hepato‐cellular carcinoma after operation

作　　者：董敏[1] 吴东昊[1] 江婷[2] 吴祥元[1] Dong Min;Wu Donghao;Jiang Ting;Wu Xiangyuan(Department of Medical Oncology,the Third Affiliated Hospital of Sun Yat‐sen University,Guangzhou 510630,China;Department of Radiology,the Third Affiliated Hospital of Sun Yat‐sen University,Guangzhou 510630,China)

机构地区：[1]中山大学附属第三医院肿瘤内科,广州510630 [2]中山大学附属第三医院放射科,广州510630

出　　处：《中华消化外科杂志》2021年第S02期5-9,共5页Chinese Journal of Digestive Surgery

基　　金：广东省自然科学基金(2017A030313537)

摘　　要：肝细胞癌术后复发率高,复发后常无再次手术机会,以系统性治疗为主。传统系统性治疗如靶向治疗和化疗的效果欠佳,预后差。笔者报道1例术后复发肝细胞癌病人根据最新IMbrave150研究结果,采用阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗的临床经验,其研究结果显示:肿瘤迅速获得部分缓解,并持续部分缓解时间>1年,不良反应小,效果良好。Hepatocellular carcinoma(HCC)has a high recurrence rate after surgical resection.There is little chance for patients with recurrent HCC to receive surgery again,and the main therapy is systemic treatment.However,the efficacy of traditional systemic treatments such as targeted therapy and chemotherapy is limited and the prognosis of patients with advanced HCC is poor.The authors reported a HCC patient who relapsed after surgical resection achieved partial remission with first‐line treatment of atelizumab and bevacizumab,according to the latest report of Imbrave150 study.The patient has maintained partial response for more than 1 year,with mild adverse reactions and good efficacy.

关 键 词：肝肿瘤 原发性 免疫治疗 靶向治疗 阿替利珠单克隆抗体 贝伐珠单克隆抗体 

分 类 号：R735.7[医药卫生—肿瘤]